

# Consumer-Directed Care Puts Focus on Prices

BY ELAINE ZABLOCKI  
Contributing Writer

SAN DIEGO — The growth of consumer-directed health plans means that physicians and their staff will need to talk more with patients about their prices and the value of their services.

“Admitting-office conversations will change dramatically,” Gary Scott Davis, a health lawyer based in Miami, said during the annual meeting of the American Health Lawyers Association. “Physicians need to develop systems that allow them to quote prices for services. ‘Complexity’ is no longer an excuse.”

Consumer-directed health care is growing rapidly, Mr. Davis said. This means pre-certification and utilization review will become less important, while the financial interface will become more important. The consumer will be paying a higher percentage of the cost of care. The new system resembles traditional indemnity insurance, and the issue is no longer whether a physician is authorized to provide a service.

**‘Admitting-office conversations will change dramatically. ... Physicians need to develop systems that allow them to quote prices for services.’**

Instead, the question becomes how much will be paid, and from whom will the fee be collected. Consumer expectations will have to change dramatically. Patients now are used to paying a standard, minimal copayment for an office visit, medication, or hospitalization. Under consumer-directed care, when patients go in for elective surgery, they’ll need to bring their credit cards with them and be prepared to spend thousands of dollars.

This shift from fixed copayments to high out-of-pocket payments means physicians and hospitals will need to develop systems to collect money from patients at the time of service and find out accurately and efficiently from third-party payers exactly how much to charge.

“The dollar amounts are higher, so bad debt could accumulate and become a more significant percentage of the physician’s bottom line,” Mr. Davis said in an interview. “Physicians will need to become ever more vigilant.”

Consumer-directed plans often include a tax-deductible health savings account to be used for medical expenses, but that does not necessarily mean the physician can access those funds, Mr. Davis explained. Some people, especially high earners, may choose to use the account as a tax-deferred savings vehicle and pay for services with other funds.

Consumer-directed care is structured to require the highest cost-sharing for services in which consumer decisions can make a difference, such as outpatient elective procedures, Mr. Davis said.

Historically, consumers have trusted their physicians’ advice and judgment.

Now, health plans or third parties may provide information that gives consumers a different perspective.

In situations in which patients do have choices, physicians who offer different services for the same diagnosis are likely to find themselves in competition. For example, a patient with cardiac problems can seek outpatient angiography from a cardiologist or get a 16-slice CT scan from a radiologist. “In the past, consumers knew that all their friends had angiography, but

now they are being given more information,” Mr. Davis said in an interview. “As they become aware that the same diagnostic service is available as a less expensive, noninvasive procedure, and they’re paying 20% of the bill, they will ask themselves whether they want to pay for the lower-cost or higher-cost procedure.”

Physicians, too, may choose to provide information about the benefits of certain procedures. “If you are a physician who believes in your heart of hearts that mas-

tectomy is the correct treatment for a certain stage of breast cancer, then you’ll want information out there saying why you think your treatment recommendations are correct,” Mr. Davis said.

Physicians and hospitals “must provide information in a way a reasonably prudent person can understand,” he said. “One of the great unknowns is potential liability. To the extent that this process is about changing consumer choices, you need to be careful.” ■

**IN ADVANCED PARKINSON'S DISEASE (PD)**

## MIRAPEX in combination with levodopa improves functioning and reduces the levodopa dose<sup>1,2</sup>

**Improves functioning by reducing treatment-related complications<sup>1,2</sup>**

**WHEN USED WITH LEVODOPA, MIRAPEX SIGNIFICANTLY REDUCES TREATMENT-RELATED COMPLICATIONS (IE, MOTOR COMPLICATIONS SUCH AS DYSKINESIA AND “OFF” TIME) AS MEASURED BY UPDRS<sup>1</sup> PART IV<sup>1</sup>**

Treatment Group	Percent Improvement
levodopa + MIRAPEX (n=179)	24%
levodopa + placebo (n=172)	3%

*P* ≤ .0001

\*UPDRS=Unified Parkinson's Disease Rating Scale

**Save levodopa for when it's really needed<sup>1</sup>**

- When used with levodopa, MIRAPEX significantly decreased the levodopa dose vs placebo (27% vs 5%, *P* ≤ .0001)<sup>1</sup>

Multicenter, double-blind, placebo-controlled, randomized, 32-week trial of 360 patients (ITT cohort=351) with advanced idiopathic PD (Hoehn and Yahr stages II-IV) on stable doses of levodopa experiencing motor fluctuations. Dosing: MIRAPEX was titrated up to 4.5 mg/d. Analysis: primary endpoints were change from baseline to final maintenance visit of average “on” and “off” ratings for UPDRS parts II and III. Secondary endpoints included change from baseline to final maintenance visit of UPDRS parts I and IV.

MIRAPEX is indicated for the treatment of the signs and symptoms of idiopathic Parkinson’s disease. Patients have reported falling asleep without perceived warning signs during activities of daily living, including operation of a motor vehicle, which sometimes resulted in accidents. Hallucinations and postural (orthostatic) hypotension may occur. The most commonly reported adverse events in early and late disease in clinical trials were dizziness, dyskinesia, extrapyramidal syndrome, hallucinations, headache, insomnia, somnolence, and nausea.

**References:** 1. Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson’s disease: results of a double-blind, placebo-controlled, parallel-group study. *Neurology*. 1997;49:162-168. 2. Pinter MM, Pogarell O, Oertel WH. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson’s disease: a double blind, placebo controlled, randomised, multicentre study. *J Neurol Neurosurg Psychiatry*. 1999;66:436-441.

Please see Brief Summary of Prescribing Information on adjacent page.



**Mirapex**<sup>®</sup>  
pramipexole dihydrochloride tablets